Share this article
Share this article
ABBOTT PARK, Ill., April 8, 2021 /PRNewswire/ Abbott (NYSE: ABT) today announced it has received CE Mark for its next-generation TriClip™ Transcatheter Tricuspid Valve Repair System, the first-of-its-kind minimally invasive tricuspid heart valve repair device available in Europe to treat tricuspid regurgitation (TR). The clip-based therapy, known as TriClip G4, is a non-surgical heart valve repair option specifically designed for the treatment of TR, or a leaky tricuspid valve, that allows physicians to tailor repair of the valve to each patient s unique anatomy.
Often referred to as the forgotten valve because of historically limited treatment options, the tricuspid valve has three leaflets that control the flow of blood between the two chambers on the right side of the heart (right ventricle and right atrium). When those leaflets do not close properly, blood can flow in the reverse direction – known as regurgitation – forcing the
Germany
Leipzig
Sachsen
Canada
Mike-dale
Philipp-lurz
Linkedin
University-of-leipzig
Facebook
Heart-center-leipzig
Health-canada
Transcatheter-tricuspid-valve-repair-system